METiS TechBio’s blockbuster IPO signals rising investor interest in AI startups focused on how drugs are delivered inside the body
Updated
May 14, 2026 3:02 PM
HIV-1 virus particles, coloured red. PHOTO: UNSPLASH
Investors are beginning to place bigger bets on AI startups focused on drug delivery infrastructure rather than drug discovery alone. That shift was on display this week after METiS TechBio, a Hong Kong tech-bio startup focused on AI-powered drug delivery systems, debuted on the Hong Kong Stock Exchange.
The listing made METiS TechBio the world’s first publicly traded AI-powered drug delivery startup and the first AI-powered large-molecule biopharmaceutical startup listed in Hong Kong. The startup raised more than HKD 2.1 billion through its IPO, making it the largest healthcare listing in Hong Kong so far in 2026.
Investor demand was unusually strong. The Hong Kong public offering was oversubscribed by more than 6,900 times while the international tranche recorded 82 times oversubscription. More than 280 institutional investors participated in the international placing.
The strong demand reflects a wider shift in AI biotech. Over the past few years, much of the sector’s attention has focused on using AI to discover new drugs or molecules. METiS is taking a different approach. The startup focuses on how medicines are delivered inside the body after they are developed.
That challenge is becoming harder to ignore in biotech. Designing a therapy is only one part of the process. Delivering it precisely to specific organs, tissues or cells remains a major hurdle, especially for newer therapies involving RNA, proteins and large-molecule drugs.
METiS is trying to solve that problem through its proprietary NanoForge platform. The system uses AI to design and test nanodelivery systems that help medicines reach targeted areas inside the body more efficiently. The platform combines AI models, simulation systems and high-throughput screening tools to speed up formulation development and improve delivery precision.
The startup says it has already achieved targeted delivery across eight organs and tissue systems including the liver, lungs, heart, muscles and central nervous system.
One of its lead programs, MTS-004, became China’s first AI-enabled formulation drug to complete a Phase III clinical trial. The drug is being developed for pseudobulbar affect, a neurological condition that affects emotional expression. According to the startup, AI tools helped reduce preclinical formulation development time from up to two years to less than three months.
Investor interest in the IPO also came from some of the world’s largest asset managers and healthcare funds. BlackRock led the cornerstone investments with a USD 50 million subscription. Other participating investors included UBS Asset Management Singapore, Mirae Asset, ORIX Corporation, Deerfield, RTW, Hillhouse Capital and IDG Capital.
METiS is also building what it describes as a “platform collaboration + product partnership” business model. The startup currently works with more than 30 pharmaceutical and biotechnology partners globally, including large pharmaceutical companies and medical research institutions.
The company reported RMB 105 million in revenue in 2025, largely tied to upfront payments connected to its MTS-004 partnership agreements. It also said some platform collaboration contracts could reach milestone values of up to USD 109 million.
Chris Lai said: "The future of biomedicine will no longer be simply about 'taking medicine when one falls ill.' METiS TechBio's ambition is to harness AI to build nano-rockets that can navigate with precision through the inner space of the human body's 30 trillion cells, write the code of nucleic acids and proteins into cells, and reprogram diseased and aging cells into healthy cells. This was our founding aspiration, and it is the mission to which we will dedicate our lives. The IPO marks a new starting point for us to accelerate forward, and we will strive to live up to the support and trust we have received from all sectors."
The IPO also highlights how Hong Kong is increasingly positioning itself as a hub for next-generation biotech and AI healthcare startups. While investor excitement around AI drug discovery has cooled in parts of the market, startups focused on delivery systems and biotech infrastructure are beginning to attract stronger institutional backing.
For METiS, the challenge now will be turning that investor confidence into commercially viable therapies and long-term partnerships. But the listing suggests that AI-driven drug delivery is starting to emerge as a category investors are willing to treat as core biotech infrastructure rather than a niche research experiment.
Keep Reading
The funding highlights how service robotics is shifting from niche deployments to scaled commercial use across global markets
Updated
May 14, 2026 3:02 PM
An autonomous service robot with a cat face design standing inside a McDonalds restaurant. PHOTO: ADOBE STOCK
Pudu Robotics, a Shenzhen-based startup building robots for commercial environments, has raised nearly US$150 million in a new funding round, pushing its valuation past US$1.5 billion. The raise brings the company’s total funding to more than US$300 million.
The company focuses on service robotics across sectors such as delivery, cleaning and industrial logistics. Its systems are used in places like retail stores, warehouses and public venues where routine tasks can be automated. Over time, Pudu has expanded from single-purpose machines to a broader portfolio that combines hardware with AI-driven navigation and coordination.
The funding is expected to support several areas of growth. These include further development of its AI systems, expansion of its product range and continued international rollout. The company also plans to invest in manufacturing and supply chain capacity, suggesting a focus on scaling production alongside demand.
Pudu’s recent growth provides some context for the raise. The company reported a doubling of revenue by 2025, with its cleaning robots now accounting for the majority of its business. Its industrial delivery robots have also seen early traction, with thousands of units deployed within a year of launch.
Its products are already in use with large global retailers including Carrefour, Walmart and EDEKA. Industry estimates place Pudu among the largest players in commercial service robotics, with a leading share of the global market.
Technically, the company develops much of its core stack in-house, including navigation systems, multi-robot coordination software and motion control. This allows its robots to operate in complex real-world environments where multiple machines need to move and work together.
“This financial milestone is a powerful confirmation of Pudu’s industry leadership, the strength of its products and technology, its global brand, and its commercial infrastructure. With the support of our strategic investors and industry partners, Pudu will continue to push the boundaries of embedded AI and business service robotics. We remain committed to innovating with an inventor’s spirit and leveraging a global vision to accelerate robot adoption, thereby elevating the industry to new heights in the global value chain”. said Felix Zhang, founder and CEO of Pudu Robotics.
The funding round points to a broader shift in the sector. As service robotics moves from pilot deployments to wider adoption, companies are increasingly being judged on their ability to scale production and operate across markets, not just on the novelty of their technology.